These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 24841216)

  • 21. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review.
    Scribano ML; Cantoro L; Marrollo M; Cosintino R; Kohn A
    J Clin Gastroenterol; 2014 Jul; 48(6):530-3. PubMed ID: 24667589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
    Cosnes J; Bourrier A; Laharie D; Nahon S; Bouhnik Y; Carbonnel F; Allez M; Dupas JL; Reimund JM; Savoye G; Jouet P; Moreau J; Mary JY; Colombel JF;
    Gastroenterology; 2013 Oct; 145(4):758-65.e2; quiz e14-5. PubMed ID: 23644079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
    Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ;
    Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy.
    Hall B; Holleran G; Chin JL; Smith S; Ryan B; Mahmud N; McNamara D
    J Crohns Colitis; 2014 Dec; 8(12):1601-9. PubMed ID: 25257546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective.
    Allen PB; Bonovas S; Danese S; Peyrin-Biroulet L
    Expert Opin Biol Ther; 2020 Feb; 20(2):151-161. PubMed ID: 31815548
    [No Abstract]   [Full Text] [Related]  

  • 26. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
    Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
    Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
    Kiss LS; Szamosi T; Molnár T; Miheller P; Lakatos L; Vincze A; Palatka K; Bartha Z; Gasztonyi B; Salamon A; Horváth G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovász BD; Végh Z; Golovics PA; Szathmári M; Papp M; Lakatos PL
    Orv Hetil; 2011 Sep; 152(36):1433-42. PubMed ID: 21865144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid?
    Fascì Spurio F; Aratari A; Margagnoni G; Doddato MT; Papi C
    J Gastrointestin Liver Dis; 2012 Mar; 21(1):67-73. PubMed ID: 22457862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P; Van Assche G; Sandborn WJ; Wolf DC; Geboes K; Colombel JF; Reinisch W; ; Kumar A; Lazar A; Camez A; Lomax KG; Pollack PF; D'Haens G
    Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An analysis of the placebo effect in Crohn's disease over time.
    Gallahan WC; Case D; Bloomfeld RS
    Aliment Pharmacol Ther; 2010 Jan; 31(1):102-7. PubMed ID: 19691670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
    Schreiber S; Rutgeerts P; Fedorak RN; Khaliq-Kareemi M; Kamm MA; Boivin M; Bernstein CN; Staun M; Thomsen OØ; Innes A;
    Gastroenterology; 2005 Sep; 129(3):807-18. PubMed ID: 16143120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of intestinal resection on quality of life in Crohn's disease.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Sparrow MP; Florin TH; Gibson PR; Debinski H; Gearry RB; Macrae FA; Leong RW; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Desmond PV
    J Crohns Colitis; 2015 Jun; 9(6):452-62. PubMed ID: 25855073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natalizumab induction and maintenance therapy for Crohn's disease.
    Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
    N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.
    Ehrenpreis ED; Kane SV; Cohen LB; Cohen RD; Hanauer SB
    Gastroenterology; 1999 Dec; 117(6):1271-7. PubMed ID: 10579967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging issues in the medical management of Crohn's disease.
    Targownik LE; Coneys JG; Dhillon AS
    Curr Opin Gastroenterol; 2016 Mar; 32(2):103-9. PubMed ID: 26839964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
    D'Haens GR; Fedorak R; Lémann M; Feagan BG; Kamm MA; Cosnes J; Rutgeerts PJ; Marteau P; Travis S; Schölmerich J; Hanauer S; Sandborn WJ;
    Inflamm Bowel Dis; 2009 Oct; 15(10):1599-604. PubMed ID: 19653291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review: the role of tacrolimus in the management of Crohn's disease.
    McSharry K; Dalzell AM; Leiper K; El-Matary W
    Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1282-94. PubMed ID: 21999607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.